REFERENCES
- American Psychiatric Association, and American Psychiatric Association Task Force on DSM-IV. (2000). Diagnostic and statistical manual of mental disorders: DSM-IV-TR (4th ed.). Washington, DC: American Psychiatric Association.
- Bablenis, E., Weber, S. S., & Wagner, R. L. (1989). Clozapine: A novel antipsychotic agent. DICP, 23, 109–115.
- Ereshefsky, L., Watanaben M. D., & Tran-Johnson, T. K. (1989). Clozapine: An atypical antipsychotic agent. Clinical Pharmacy, 8, 691–709.
- Fasano, A., & Petrovic, I. (2010). Insights into pathophysiology of punding reveal possible treatment strategies. Molecular Psychiatry, 15, 560–573.
- Fasano, A., Ricciardi, L., Pettorruso, M., & Bentivoglio, A. R. (2011). Management of punding in Parkinson’s disease: An open-label prospective study. Journal of Neurology, 258, 656–660.
- Friedman, J. H. (1994). Punding on levodopa. Biological Psychiatry, 36, 350–351.
- Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992). Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: A clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery and Psychiatry, 55, 181–184.
- Kashihara, K., & Imamura, T. (2008). Amantadine may reverse punding in Parkinson’s disease – observation in a patient. Movement Disorders, 23, 129–130.
- Klos, K. J., Bower, J. H., Josephs, K. A., Matsumoto, J. Y., & Ahlskog, J. E. (2005). Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson’s disease and multiple system atrophy. Parkinsonism & Related Disorders, 11, 381–386.
- Kornhuber, J., Bormann, J., Hübers, M., Rusche, K., & Riederer, P. (1991). Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: A human postmortem brain study. European Journal of Pharmacology, 206, 297–300.
- Lowe, J. A., Seeger, T. F., & Vinick, F. J. (1988). Atypical antipsychotics – recent findings and new perspectives. Medicinal Research Reviews, 8, 475–497.
- Lyons, K. E., Friedman, J. H., Hermanowicz, N., Isaacson, S. H., Hauser, R. A., Hersh, B. P., … Pahwa, R. (2010). Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects. Clinical Neuropharmacology, 33, 5–10.
- Mallet, L., Mesnage, V., Houeto, J. L., Pelissolo, A., Yelnik, J., Behar, C., Gargiulo, M., Welter, M. L., Bonnet, A. M., Pillon, B., … Agid, Y. (2002). Compulsions, Parkinson’s disease, and stimulation. Lancet, 360, 1302–1304.
- Mamikonyan, E., Siderowf, A. D., Duda, J. E., Potenza, M. N., Horn, S., Stern, M. B., & Weintraub, D. (2008). Long-term follow-up of impulse control disorders in Parkinson’s disease. Movement Disorders, 23, 75–80.
- Microdex Healthcare Series [Intranet database] 2.0. (2002–2011). Greenwood Village, CO: Thomson Reuters (Healthcare).
- O’Sullivan, S. S., Evans, A. H., & Lees, A. J. (2007). Punding in Parkinson’s disease. Practical Neurology, 7, 397–399.
- Rotondo, A., Bosco, D., Plastino, M., Consoli, A., & Bosco, F. (2010). Clozapine for medication-related pathological gambling in Parkinson disease. Movement Disorders, 25, 1994–1995.
- Sevincok, L., Akoglu, A., & Akyol, A. (2007). Quetiapine in a case with Parkinson disease and pathological gambling. Journal of Clinical Psychopharmacology, 27, 107–108.